<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2022-5149</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИКА И ФАРМАКОТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINIC AND PHARMACOTHERAPY</subject></subj-group></article-categories><title-group><article-title>Частота использования пероральных антикоагулянтов в реальной клинической практике у пациентов, госпитализированных с острым ишемическим инсультом</article-title><trans-title-group xml:lang="en"><trans-title>Prevalence of oral anticoagulant therapy in clinical practice in patients hospitalized with acute ischemic stroke</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6796-212X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тавлуева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tavlueva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, руководитель регионального сосудистого центра.</p><p>Москва</p></bio><bio xml:lang="en"><p>Head of the Regional Vascular Center.</p><p>Moscow</p></bio><email xlink:type="simple">tavlev1@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8256-5686</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савкова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Savkova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Заведующий отделением неврологии для больных острым нарушением мозгового кровообращения регионального сосудистого центра.</p><p>Москва</p></bio><bio xml:lang="en"><p>Head of the neurology department.</p><p>Moscow</p></bio><email xlink:type="simple">olga.savkova@inbox.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4565-6743</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зернова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zernova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-кардиолог отделения кардиологии для больных с острым инфарктом миокарда.</p><p>Москва</p></bio><bio xml:lang="en"><p>Cardiologist, Department of Cardiology for patients with Acute Myocardial Infarction.</p><p>Moscow</p></bio><email xlink:type="simple">evgenya.gor@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1002-1895</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бернс</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Berns</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор кафедры терапии и общей врачебной практики.</p><p>Москва</p></bio><bio xml:lang="en"><p>Рrofessor at the Department of Therapy and General Medical Practice.</p><p>Moscow</p><p> </p></bio><email xlink:type="simple">svberns@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4453-8430</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Драпкина</surname><given-names>О. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Drapkina</surname><given-names>O. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, академик РАН, директор.</p><p>Москва</p></bio><bio xml:lang="en"><p>Chief Internal Medicine and General Practice Specialist of the Ministry of Health of the Russian Federation, Academic of the of the Russian Academy of Science.</p><p>Moscow</p></bio><email xlink:type="simple">drapkina@bk.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ Городская клиническая больница им. Ф.И. Иноземцева Департамента здравоохранения города Москвы; ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>F.I. Inozemtsev City Clinical Hospital; National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ Городская клиническая больница им. Ф.И. Иноземцева Департамента здравоохранения города Москвы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>F.I. Inozemtsev City Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>04</day><month>01</month><year>2023</year></pub-date><volume>27</volume><issue>12</issue><fpage>5149</fpage><lpage>5149</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тавлуева Е.В., Савкова О.Н., Зернова Е.В., Бернс С.А., Драпкина О.М., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Тавлуева Е.В., Савкова О.Н., Зернова Е.В., Бернс С.А., Драпкина О.М.</copyright-holder><copyright-holder xml:lang="en">Tavlueva E.V., Savkova O.N., Zernova E.V., Berns S.A., Drapkina O.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5149">https://russjcardiol.elpub.ru/jour/article/view/5149</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить частоту назначения прямых оральных антикоагулянтов на амбулаторном и стационарном этапах у пациентов, госпитализированных с острым нарушением мозгового кровообращения (ОНМК) по ишемическому типу.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В открытое обсервационное проспективное исследование в условиях реальной клинической практики включено 114 больных с фибрилляцией предсердий (ФП), госпитализированных с подтвержденным ОНМК.</p></sec><sec><title>Результаты</title><p>Результаты. Только 26,3% больных с ФП, госпитализированных с подтвержденным диагнозом ишемического инсульта, принимали антикоагулянты (из них 70% — ПОАК, 30% — варфарин). При этом среди принимающих варфарин только у одного больного международное нормализованное отношение (МНО) оказалось в пределах нормативных значений на момент госпитализации (МНО 2,6). Во всех остальных случаях МНО было &lt;2. Из 105 пациентов, выписанных на амбулаторный этап, 93 (88,6%) больным назначены антикоагулянты, причем в большинстве случаев (89 (84,8%)) были назначены ПОАК. 4 (3,8%) пациентов настояли на продолжении приема варфарина. Причины неназначения пероральных антикоагулянтов: 4 (33,3%) пациентам была диагностирована в период госпитализации язвенная болезнь в стадии обострения, 2 (16,7%) — геморрагическая трансформация ишемического очага.</p></sec><sec><title>Заключение</title><p>Заключение. Одной из частых причин развития ОНМК у пациентов с ФП остается отказ от приема пероральных антикоагулянтов на амбулаторном этапе или отсутствие достаточного контроля МНО при приеме варфарина.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the prevalence of oral anticoagulant therapy at the outpatient and inpatient stages in patients hospitalized with ischemic stroke.</p></sec><sec><title>Material and methods</title><p>Material and methods. This open observational prospective real-world study included 114 patients with atrial fibrillation (AF) hospitalized with confirmed stroke.</p></sec><sec><title>Results</title><p>Results. Only 26,3% of patients with AF hospitalized with a confirmed diagnosis of ischemic stroke took anticoagulants (70% — direct oral anticoagulants (DOACs), 30% — warfarin). At the same time, among those taking warfarin, only one patient had normal international normalized ratio (INR) at the time of hospitalization (INR 2,6). In all other cases, the INR was &lt;2. Of the 105 patients discharged at the outpatient stage, 93 (88,6%) patients were prescribed anticoagulants, and in most cases — DOACs (89 (84,8%)). 4 (3,8%) patients insisted on continuing warfarin therapy. There were following reasons for not prescribing DOACs: 4 (33,3%) patients were diagnosed with acute peptic ulcer during hospitalization, 2 (16,7%) — hemorrhagic transformation of the ischemic focus.</p></sec><sec><title>Conclusion</title><p>Conclusion. One of the common reasons for stroke in outpatients with AF is the refusal to take oral anticoagulants or insufficient INR control when taking warfarin.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>инсульт</kwd><kwd>антикоагулянты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>stroke</kwd><kwd>anticoagulants</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-e528. doi:10.1161/cir.0000000000000659.</mixed-citation><mixed-citation xml:lang="en">Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation. 2019;139:e56-e528. doi:10.1161/cir.0000000000000659.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Staerk L, Sherer JA, Ko D. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120:1501-17. doi:10.1161/circresaha.117.309732.</mixed-citation><mixed-citation xml:lang="en">Staerk L, Sherer JA, Ko D. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res. 2017;120:1501-17. doi:10.1161/circresaha.117.309732.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez CJ, Soliman EZ, Alonso A, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015;25:71-6.e1. doi:10.1016/j.annepidem.2014.11.024.</mixed-citation><mixed-citation xml:lang="en">Rodriguez CJ, Soliman EZ, Alonso A, et al. Atrial fibrillation incidence and risk factors in relation to race-ethnicity and the population attributable fraction of atrial fibrillation risk factors: the Multi-Ethnic Study of Atherosclerosis. Ann Epidemiol. 2015;25:71-6.e1. doi:10.1016/j.annepidem.2014.11.024.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yiin GSC, Li L, Bejot Y, Rothwell PM. Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation. Stroke. 2019;50:21-7. doi:10.1161/strokeaha.118. 022249.</mixed-citation><mixed-citation xml:lang="en">Yiin GSC, Li L, Bejot Y, Rothwell PM. Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation. Stroke. 2019;50:21-7. doi:10.1161/strokeaha.118.022249.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes. 2019;5:35-42. doi:10.1093/ehjqcco/qcy033.</mixed-citation><mixed-citation xml:lang="en">An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: the Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes. 2019;5:35-42. doi:10.1093/ehjqcco/qcy033.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Asso ciation of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and mana gement of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.</mixed-citation><mixed-citation xml:lang="en">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Asso ciation of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and mana gement of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2021;42(5):373-498. doi:10.1093/eurheartj/ ehaa612.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146:857-67. doi:10.7326/0003-4819-146-12-200706190-00007.</mixed-citation><mixed-citation xml:lang="en">Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146:857-67. doi:10.7326/0003-4819-146-12-200706190-00007.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955-62. doi:10.1016/s0140-6736(13) 62343-0.</mixed-citation><mixed-citation xml:lang="en">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955-62. doi:10.1016/s0140-6736(13) 62343-0.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Скирденко Ю. П., Николаев Н. А. Вклад приверженности терапии антикоагулянтами в риск осложнений фибрилляции предсердий. Российский кардиологи ческий журнал. 2019;(2):64-9. doi:10.15829/1560-4071-20192-64-69.</mixed-citation><mixed-citation xml:lang="en">Skirdenko YuP, Nikolaev NA. The contribution of adherence to anticoagulant therapy at the risk of complications of atrial fibrillation. Russian Journal of Cardiology. 2019;(2):64-9. (In Russ.) doi:10.15829/1560-4071-20192-64-69.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/15604071-2021-4594.</mixed-citation><mixed-citation xml:lang="en">Аtrial fibrillation. Clinical guidelines 2020. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.) doi:10.15829/15604071-2021-4594.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J. 2019;213:35-46. doi:10.1016/j.ahj.2019.03.013.</mixed-citation><mixed-citation xml:lang="en">Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J. 2019;213:35-46. doi:10.1016/j.ahj.2019.03.013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jerjes-Sanchez C, Corbalan R, Barretto ACP, et al. GARFIELD-AF Investigators. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clin Cardiol. 2019;42(5):553-60. doi:10.1002/clc.23176.</mixed-citation><mixed-citation xml:lang="en">Jerjes-Sanchez C, Corbalan R, Barretto ACP, et al. GARFIELD-AF Investigators. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. Clin Cardiol. 2019;42(5):553-60. doi:10.1002/clc.23176.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cools F, Wollaert B, Vervoort G, et al. GARFIELD-AF Investigators. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: re sults from the GARFIELD-AF registry. Acta Cardiol. 2019;74(4):309-18. doi:10.1080/00015385.2018.1494089.</mixed-citation><mixed-citation xml:lang="en">Cools F, Wollaert B, Vervoort G, et al. GARFIELD-AF Investigators. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: re sults from the GARFIELD-AF registry. Acta Cardiol. 2019;74(4):309-18. doi:10.1080/00015385.2018.1494089.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Марцевич С. Ю., Навасардян А. Р., Кутишенко П., Захарова А. В. Оценка приверженности к приему новых пероральных антикоагулянтов у пациентов с фибрилляцией предсердий по данным регистра Профиль. Рациональная фармакотерапия в кардио логии. 2014;10(6):625-30. doi:10.20996/1819-6446-201410-6-625-630.</mixed-citation><mixed-citation xml:lang="en">Marcevich SYu, Navasardyan AR, Kutishenko P, Zaharova AV. Assessment of adherence to new oral anticoagulants in patients with atrial fibrillation according to the Profile register. Rational pharmacotherapy in cardiology. 2014;10(6):625-30. (In Russ.) doi:10.20996/1819-6446-201410-6-625-630.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Золотовская И. А., Давыдкин И. Л., Дупляков Д. В. Антикоагулянтная терапия у пациентов с фибрилляцией предсердий, перенесших кардиоэмболический инсульт: оценка приверженности к антикоагулянтной терапии в реальной клинической практике (Результаты когортного исследования "АПОЛЛОН"). Российский кардиологический журнал. 2017;(7):105-10. doi:10.15829/1560-4071-2017-7-105-110.</mixed-citation><mixed-citation xml:lang="en">Zolotovskaya IA, Davydkin IL, Duplyakov DV. Anticoagulant therapy in patients with atrial fibrillation after cardioembolic stroke: assessment of adherence to anticoagulant therapy in real clinical practice (Results of the APOLLO cohort study). Russian Journal of Cardiology. 2017;(7):105-10. (In Russ.) doi:10.15829/1560-4071-2017-7-105-110.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
